{"brief_title": "Trial of VLTS-589 in Subjects With Intermittent Claudication", "brief_summary": "The purpose of this study is to evaluate the safety and tolerability of VLTS-589 compared with placebo, administered bilaterally to the lower extremities, in subjects with intermittent claudication and to determine the effect of VLTS-589 in peak walking time (PWT) for subjects receiving VLTS-589 compared with subjects receiving placebo.", "condition": ["Intermittent Claudication", "Peripheral Vascular Disease"], "intervention_type": ["Genetic"], "intervention_name": ["Plasmid based Gene Transfer product-VLTS-589"], "criteria": "Inclusion criteria: - Men or women between 40 and 80 years of age, - Must give informed consent, - Current medical history of peripheral arterial disease, which includes the following symptoms: leg pain, leg discomfort or leg weakness Exclusion criteria: - Ulcers or gangrene, - History of cancer (except skin cancer) within the past 5 years, - Participation in another clinical trial within 30 days of enrollment in this trial, - Unwillingness or inability to comply with all study requirements", "gender": "All", "minimum_age": "40 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "mesh_term": ["Vascular Diseases", "Peripheral Arterial Disease", "Intermittent Claudication", "Peripheral Vascular Diseases"], "id": "NCT00068133"}